Carboplatin dosage: prospective evaluation of a simple formula based on renal function.
暂无分享,去创建一个
E Wiltshaw | A H Calvert | M. Gore | I. Judson | Z. Siddik | D. Newell | A. Calvert | D R Newell | E. Wiltshaw | L A Gumbrell | S O'Reilly | M Burnell | F E Boxall | Z H Siddik | I R Judson | M E Gore | I. Judson | A. H. Calvert | M. Burnell | S. O’Reilly | Z. Siddik | F. E. Boxall | L. Gumbrell | M. Gore | F. Boxall | S. O'Reilly
[1] J. Bull,et al. Kinetics of cis‐dichlorodiammineplatinum , 1979, Clinical pharmacology and therapeutics.
[2] H. Piaggio,et al. An elementary treatise on differential equations and their applications , 1920 .
[3] H. Pinedo,et al. Comparative pharmacokinetics of cisplatin and three analogues in mice and humans. , 1987, Cancer research.
[4] B. Leyland-Jones,et al. Results of NCI-sponsored phase I trials with carboplatin. , 1985, Cancer treatment reviews.
[5] H. Pinedo,et al. Pharmacokinetics of diammine(l,l cyclobutanedi carboxylato) platinum(II) (carboplatin) after intravenous administration , 1987 .
[6] S. Carter,et al. Carboplatin: the clinical spectrum to date. , 1985, Cancer treatment reviews.
[7] Z. Siddik,et al. The comparative pharmacokinetics of carboplatin and cisplatin in mice and rats. , 1987, Biochemical pharmacology.
[8] K. Harrap. Preclinical studies identifying carboplatin as a viable cisplatin alternative. , 1985, Cancer treatment reviews.
[9] K. Eguchi,et al. Prediction of hematologic toxicity of carboplatin by creatinine clearance rate. , 1987, Japanese journal of cancer research : Gann.
[10] M. Rozencweig,et al. Carboplatin: current status and future prospects. , 1988, Cancer treatment reviews.
[11] F. Cavalli,et al. Iproplatin and carboplatin induced toxicities: overview of phase II clinical trial conducted by the EORTC Early Clinical Trials Cooperative Group (ECTG). , 1988, European journal of cancer & clinical oncology.
[12] E. Wiltshaw,et al. Ovarian trials at the Royal Marsden. , 1985, Cancer treatment reviews.
[13] D. Newell,et al. Phase I studies with carboplatin at the Royal Marsden Hospital. , 1985, Cancer treatment reviews.
[14] W. Rose,et al. Preclinical antitumor and toxicologic profile of carboplatin. , 1985, Cancer treatment reviews.
[15] M. Egorin,et al. Prospective validation of a pharmacologically based dosing scheme for the cis-diamminedichloroplatinum(II) analogue diamminecyclobutanedicarboxylatoplatinum. , 1985, Cancer research.
[16] N Veall,et al. Glomerular filtration rate measurement in man by the single injection methods using 51Cr-EDTA. , 1969, Clinical science.
[17] J. Koeller,et al. Phase I clinical trial and pharmacokinetics of carboplatin (nsc 241240) by single monthly 30‐minute infusion , 1986, Cancer.
[18] W. Evans,et al. Clinical pharmacodynamics of continuous infusion teniposide: systemic exposure as a determinant of response in a phase I trial. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] R. Ozols,et al. A Phase I and Pharmacokinetic Study of Diamminecyclobutanedicarboxylatoplatinum (NSC 241240) , 1983 .
[20] M. Gore,et al. Plasma free platinum pharmacokinetics in patients treated with high dose carboplatin. , 1987, European journal of cancer & clinical oncology.
[21] K. Kimura,et al. Clinical Pharmacokinetics of Carboplatin , 1988, Journal of clinical pharmacology.
[22] Z. Siddik,et al. Pharmacokinetics of cis-diammine-1,1-cyclobutane dicarboxylate platinum(II) in patients with normal and impaired renal function. , 1984, Cancer research.
[23] M. Egorin,et al. Pharmacokinetics and dosage reduction of cis-diammine(1,1-cyclobutanedicarboxylato)platinum in patients with impaired renal function. , 1984, Cancer research.
[24] B. Chabner,et al. Potential roles for preclinical pharmacology in phase I clinical trials. , 1986, Cancer treatment reports.
[25] M. Egorin,et al. Phase I clinical and pharmacologic trial of carboplatin daily for 5 days. , 1984, Cancer treatment reports.
[26] P. Welling,et al. Pharmacokinetics: Processes and Mathematics , 1986 .